• Citer

Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor–positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)

par McCartney, Amelia;Biagioni, Chiara;Schiavon, Gaia;Bergqvist, Mattias;Mattsson, Karin;Migliaccio, Ilenia;Benelli, Matteo;Romagnoli, Dario;Bonechi, Martina;Boccalini, Giulia;Pestrin, Marta;Galardi, Francesca;De Luca, Francesca;Biganzoli, Laura ;Piccart-Gebhart, Martine ;Gradishar, William W.J.;Chia, Stephen;Di Leo, Angelo ;Malorni, Luca
Référence European journal of cancer, 114, page (55-66)
Publication Publié, 2019-06

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor–positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)
Auteur:	McCartney, Amelia; Biagioni, Chiara; Schiavon, Gaia; Bergqvist, Mattias; Mattsson, Karin; Migliaccio, Ilenia; Benelli, Matteo; Romagnoli, Dario; Bonechi, Martina; Boccalini, Giulia; Pestrin, Marta; Galardi, Francesca; De Luca, Francesca; Biganzoli, Laura; Piccart-Gebhart, Martine; Gradishar, William W.J.; Chia, Stephen; Di Leo, Angelo; Malorni, Luca
Informations sur la publication:	European journal of cancer, 114, page (55-66)
Statut de publication:	Publié, 2019-06
Sujet CREF:	Cancérologie
Mots-clés:	Biomarker
	Breast cancer
	EFECT
	Endocrine resistance
	Prognosis
	Treatment response
Note générale:	SCOPUS: ar.j
	DecretOANoAutActif
Langue:	Anglais
Identificateurs:	urn:issn:0959-8049
	info:doi/10.1016/j.ejca.2019.04.002
	info:pii/S0959804919302230
	info:scp/85065012950
	info:pmid/31059974